Table 4

Change in medication use in 12 months prior to versus postinitiation of mepolizumab

MedicationPremepolizumab mean-weighted average dispensingsPre-SDPostmepolizumab mean-weighted average dispensingsPost-SDPer cent reduction (negative indicates increase)
Single controller medication
 Low ICS or medium-dose ICS0.7430.713.35
 High-dose ICS0.612.80.673.4−10
 LAMA1.33.31.64.1−22
 LTRA3.33.83.54.3−4
 Oral corticosteroids (28+ days)1.53.31.63.7−5
Combination
 ICS/LABA (any dose)2.73.32.83.8−4
 Low-dose ICS/LABA1.83.123.7−9
 Medium-dose or high-dose ICS/ LABA0.913.30.863.85
 Low-dose or medium-dose ICS/ LTRA0.342.20.332.63
ICS/LTRA
 High-dose ICS/ LTRA0.292.10.312.6−7
Biologics
 Omalizumab1.46.60.546.461
 Reslizumab0.0010.710.0283.6−4992
 Benralizumab0.0011.40.0752.5−6650
 Dupilumab0.0042.10.0363.7−712
Rescue
 Oral corticosteroids (3–27 days)3.23.52.12.835%
 SABA3.84.63.64.96%
  • Paired measurements were not available due to aggregated nature of data.

  • ICS, inhaled corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonists; SABA, short-acting beta agonist.